CNBC Interview: Inventor Dr. Rothberg on Quantum-Si SPAC deal

Quantum-Si, a Pioneer in Semiconductor Chip-Based Proteomics, to Combine with HighCape Capital Acquisition Corp.

Aziyo Biologics Announces First Patient Enrolled in HEAL Study

Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution

21 New “Kids” on the Block: The Most Recent Entrants into the Greater New Haven Biotech Hub

Wellinks Announces Initiation of IRB Approved Study of Digital Health Solution for COPD

Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation

Athena Therapeutics announces initial financing from Highcape Capital and Connecticut Innovations

Aziyo Biologics Reports Third Quarter 2020 Financial Results

Aziyo Biologics to Participate in the Piper 32nd Annual Virtual Healthcare Conference

Surgalign Holdings and Aziyo Biologics Announce Expanded Distribution Agreement

Aziyo Biologics Awarded Breakthrough Technology Contract with Premier Inc.

Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020

HighCape Capital Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about October 26, 2020

Aziyo Biologics Announces Pricing of Initial Public Offering

Aziyo Biologics Announces Appointment of Chief Financial Officer

Aziyo Biologics Announces New Appointments to Board of Directors

HighCape Capital Acquisition Corp. Announces Closing of $115 Million Initial Public Offering

HighCape Capital Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

Wellinks has been awarded 2020 Venture of the Year from the CT Entrepreneur Awards

TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

TELA Bio Announces Closing of Public Offering of Common Stock

Aziyo Biologics Announces Launch of OsteGro® V

TELA Bio Announces Pricing of Public Offering of Common Stock

TELA Bio Announces Proposed Public Offering of Common Stock

TELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS)

TELA Bio Announces Changes to its Board of Directors

Convexity Scientific Wellinks Announcement Convexity Activity

TELA Bio Appoints Federica O’Brien to Board of Directors

TELA Bio Announces Closing of Initial Public Offering of Common Stock

TELA Bio Announces Pricing of Initial Public Offering of Common Stock

Baxter International Acquires HighCape Capital Portfolio Company Cheetah Medical

TELA Bio readies IPO

Convexity Scientific raises $4m Series B for Flyp nebulizer

Baxter CEO Discussing Cheetah Acquisition

BAXTER ANNOUNCES ACQUISITION OF CHEETAH MEDICAL TO EXPAND SPECIALIZED PATIENT MONITORING PORTFOLIO

ZIP SURGICAL SKIN CLOSURE DEMONSTRATES SUPERIOR HEALTH ECONOMICS AND CLINICAL OUTCOMES COMPARED TO SURGICAL STAPLES IN TWO RECENTLY PUBLISHED CLINICAL STUDIES

Aziyo Biologics® Announces Exclusive Agreement with Medtronic® to Distribute FiberCel®

TELA Bio® to Participate in JMP Securities Life Sciences Conference

FRESH STUDY RESULTS DEMONSTRATES FLUID RESPONSIVENESS IS DYNAMIC DURING 72-HOUR SEPSIS MONITORING WINDOW

ZIPLINE MEDICAL SELECTED AS 2019 RED HERRING TOP 100 NORTH AMERICA WINNER

CHEETAH MEDICAL SHOWCASES FLUID MANAGEMENT EDUCATION WITH VIRTUAL TRAINER APP AT THE 2019 NATIONAL TEACHING INSTITUTE & CRITICAL CARE EXPOSITION

Aziyo Biologics and Boston Scientific Corporation Enter U.S. Sales Agent Agreement for CanGaroo® Envelope

TELA Bio® Appoints Kurt Azarbarzin Chairman of Board of Directors

TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery

Innovative product portfolio based on TELA Bio's proven technology platform advances the design of biologic-based materials for reconstructive surgery.

Aziyo Announces Publication of RECON Study of Pericardial Reconstruction Using ProxiCor

Prospective Study of 1,420 Patients Showed Statistically Significant Reduction in Post-Operative Complications and 30-Day Hospital Readmission Rates

TELA Bio® to Present at 18th Annual Needham Healthcare Conference

CHEETAH MEDICAL PARTNERS WITH SEPSIS ALLIANCE TO SUPPORT HEALTHCARE PROVIDER EDUCATION ON SEPSIS – THE THIRD LEADING CAUSE OF DEATH IN THE UNITED STATES

ZIPLINE MEDICAL ANNOUNCES NEW EMERGENCY DEPARTMENT STUDY SHOWING SIGNIFICANT TIME AND COST SAVINGS, AND SUPERIOR PATIENT SATISFACTION, WITH LACERATION CLOSURE USING ZIP® SURGICAL SKIN CLOSURE

FRESH STUDY RESULTS SHOW PASSIVE LEG RAISE MAY PREDICT CARDIAC DYSFUNCTION IN SEPTIC SHOCK PATIENTS

Cheetah Medical Announces Successful Completion of Key Sepsis Clinical Trial

Cheetah Medical Partners with SWC Funding LLC to Advance Commercial Operations

TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds

TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance

Nora Brennan Joins TELA Bio® as Chief Financial Officer

Nora Brennan has joined the company as chief financial officer.

Aziyo’s CanGaroo Envelope Cleared for Expanded Use with Neurostimulator Devices

The FDA clearance for CanGaroo has been expanded to include vagus nerve, deep brain and sacral nerve stimulators as well as spinal cord neuromodulators.

ZipLine Medical Announces Publication of Two Clinical Studies Demonstrating Superior Infection Protection and 22 Percent Reduction in Procedure Time with Zip Surgical Skin Closure

ZipLine Medical, Inc. today announced publication of results from two groundbreaking clinical studies.

TELA Bio® Appoints Kurt Azarbarzin to Board of Directors

Current chief technology officer of CONMED Corporation to replace vacating director Paul Touhey

TELA Bio® Announces Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair

Two papers report no hernia recurrences during postoperative period, highlight advantages in repair reinforcement and pain management.

RTI Surgical® and Aziyo® Biologics Announce Exclusive Agreement to Distribute ViBone® for Spine and Other Orthopedic Procedures

Agreement will expand availability of ViBone, a next generation cellular bone matrix product

ZipLine Medical Closes $9 Million Growth Financing Led by Existing Investor MVM Partners LLP

ZipLine Medical, Inc. today announced completion of a growth financing round totaling $9 million.

Cheetah Medical’s French Distributor SEBAC SA to Supply Starling SV Monitoring Systems to Paris’ Public Hospital System

SEBAC SA, has been awarded the contract to supply Starling SV non-invasive fluid management solutions to the public hospital system of Paris and its suburbs.

Ronald Lloyd Announced as New President and CEO of Aziyo Biologics

Seasoned leader brings a wealth of experience in commercial and business development

Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes

Lake Oswego, OR. and Silver Springs, MD. / PRNewswire

BIOTRONIK US and Aziyo today announced a strategic agreement allowing BIOTRONIK to distribute Aziyo’s CanGaroo® extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from BIOTRONIK starting in April 2018.

TELA Bio Announces Investment Agreement with ProMedica Innovations Venture Fund

TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that ProMedica, a mission-based, not-for-profit healthcare organization serving northwest Ohio and southern Michigan, has agreed to invest $1 million in TELA Bio through the ProMedica Innovations Venture Fund.

ONGOING ASSESSMENT OF FLUID RESPONSIVENESS IMPROVES CLINICAL OUTCOMES IN SEPTIC PATIENTS

Data leveraging Cheetah technology to be presented at the International Symposium on Intensive Care and Emergency Medicine in Brussels

TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction

TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that data from a retrospective study evaluating the use of RBSs in abdominal wall reconstruction (AWR) procedures show low recurrence and complication rates.

COST OF SEVERE SEPSIS AND SEPTIC SHOCK TREATMENT REDUCED BY OVER $14,000 PER PATIENT WITH CHEETAH MEDICAL TECHNOLOGY

Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management devices, today announced the first presentation of major economic data showing total cost savings of over $1.4 million during a 6-month study in severe sepsis and septic shock patients.

NEW STUDY SHOWS IMPROVED PROTOCOL REDUCED SEPSIS MORTALITY RATE BY 85 PERCENT

Sutter Solano Medical Center, in collaboration with Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management technology, today announced the presentation of new study results at the Society of Critical Care Medicine’s 47th Annual Critical Care Congress in San Antonio, Texas.

Aziyo and Cook Biotech Announce Further Expansion of the Bio Envelope Franchise into Additional Markets

Aziyo Biologics, Inc. and Cook Biotech Inc. today announced the expansion of the Aziyo Bio Envelope franchise by entering into additional exclusive global license agreements expanding the applications for the Bio Envelope product into the field of neuromodulation.

Zip Surgical Skin Closure Preferred over Staples During Bilateral Knee Surgery

ZipLine® Medical, Inc. today announced results from the first study to assess Zip® Surgical Skin Closure versus surgical staples for closure in the same patients. Results were presented today as a poster at the American Academy of Hip and Knee Surgery Annual Meeting (AAHKS) by Rodney Benner, MD, of the Shelbourne Knee Center in Indianapolis.

Confidential: HighCape Partners Annual Meeting – October 2017

There is no excerpt because this is a protected post.

TELA Bio Announces Hiring of Greg Firestone as Vice President of Strategic Customer Relations

TELA Bio, Inc., a surgical reconstruction company leading the development of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that Greg Firestone has joined the company as vice president of strategic customer relations.

NEW STUDY DEMONSTRATES THE NEED FOR GUIDED INTRAOPERATIVE FLUIDS TO IMPROVE PATIENT OUTCOMES

Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced new research results presented today at the American Society of Anesthesiologists Annual Meeting in Boston: Fluid Administration and Hospital Practice in Major Abdominal Procedures, Results from Examination of a Large Administrative Database.

Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has committed to invest up to $25 million in TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex™ portfolio of products for ventral hernia repair and abdominal wall reconstruction.

Confidential: Cybrexa Therapeutics Update – October 16, 2017

There is no excerpt because this is a protected post.

Recently Published Sepsis Study Supports Using Stroke Volume for Guiding Fluid Resuscitation Strategies While Reducing ICU Length of Stay by 33%

Cheetah Medical, a Massachusetts based leader in non-invasive hemodynamic monitoring, announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock.

Zip Surgical Skin Closure Reduces Post-Discharge Costs, Clinic Calls and Antibiotics in First Economic Study of Device

ZipLine Medical, Inc. today announced results from an economic study that showed that Zip Surgical Skin Closure reduced post-discharge costs for total knee arthroplasty (TKA) when compared to staples. Results were presented Friday at the Knee Society Members Meeting by Roger Emerson, MD, of the Texas Center for Joint Replacement, Plano, Texas.

ZipLine Medical Secures $12 Million in New Financing Led by New Investor, HighCape Partners

ZipLine Medical, Inc. today announced it completed a $12 million Series E round of financing. Proceeds from the financing will be used to continue worldwide commercialization activities for its Zip® Surgical Skin Closure products, as well as development of advanced tools to reduce post-discharge costs in a bundled care environment.

TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction Conference

TELA Bio, Inc., a surgical reconstruction company leading the development of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company will present at the MedStar Georgetown University Hospital’s Abdominal Wall Reconstruction (AWR) Conference being held June 8-10 at the JW Marriott in Washington, D.C.

Aziyo Continues Building New Breed of Regenerative Medicine Company

Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix® Cardiovascular, Inc. for the purchase of all CorMatrix commercial assets and related intellectual property.

TELA Bio Initiates BRAVO Study of OviTex™ Reinforced BioScaffolds for Hernia Repair

ELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company has initiated a post-market clinical study, BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair (BRAVO), of its OviTex™ Permanent 1S device.

CHEETAH MEDICAL ANNOUNCES RESULTS OF KEY SEPSIS STUDY

Cheetah Medical, a rapidly growing medical device company, announced the results of a major new study conducted by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Medical Center. The study was designed to evaluate fluid resuscitation in ICU patients with severe sepsis and septic shock, and results were presented this week at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels.

TELA Bio to Participate in 16th Annual Needham Healthcare Conference

TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, announced today that the company will participate in the 16th Annual Needham Healthcare Conference to be held April 4-5, 2017 at the Westin NY Grand Central Hotel in New York City.

CHEETAH MEDICAL ADVANCES THE SCIENCE OF FLUID MANAGEMENT

Cheetah Medical announced today that its eighth abstract on fluid management will be presented at Society of Critical Care Medicine meeting in January. Building on previous work, this abstract demonstrates a strong association between large volume fluid administration in septic shock and increased risk of death in more than 23,000 patients.

TELA Bio Announces Settlement of Litigation with LifeCell

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that it has settled all litigations and disputes between TELA Bio and LifeCell, and that all pending state and federal court actions between the two companies have been dismissed. Terms of the agreement are confidential.

TELA Bio Announces OviTex™ Reinforced BioScaffolds Implanted in 100 Hernia Repair Procedures

TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company’s OviTex™ RBSs have been implanted in more than 100 hernia repair procedures since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2016.

HighCape Partners 2016 Annual Meeting

There is no excerpt because this is a protected post.

Cheetah Medical Announces Supplier Agreement with Allina Health

Cheetah Medical has signed a supplier contract with Allina Health, a leading non-for-profit healthcare system serving communities throughout Minnesota and western Wisconsin. The contract enables Allina Health facilities to have access to Cheetah Medical’s hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network.

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling.

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building block derived from ovine rumen, in layered constructs designed for multi-directional cell repopulation and healthy tissue remodeling.

Results from Studies of OviTex™ Reinforced BioScaffolds Presented at Abdominal Wall Reconstruction Conference

ELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that results from three studies of the company’s OviTex™ RBSs were presented at the Abdominal Wall Reconstruction (AWR) Conference held June 9-11 in Washington, D.C. OviTex RBSs combine synthetic and biologic materials by interweaving polymer through layers of intact extracellular matrix (ECM), a biologic building block derived from ovine rumen.

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company, Aziyo Biologics, Inc. HighCape has partnered with Tissue Banks International (TBI) to create a regenerative medicine company focused on best-in-class leadership and technology. Deerfield Management Co. joined HighCape in providing capital for the transaction.

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company, Aziyo Biologics, Inc. HighCape has partnered with Tissue Banks International (TBI) to create a regenerative medicine company focused on best-in-class leadership and technology. Deerfield Management Co. joined HighCape in providing capital for the transaction.

HighCape Partners Closes Initial $80 Million Growth Equity Fund

HighCape Partners Management, L.P. today announced the final closing of HighCape Partners, L.P., its initial $80 million growth equity fund focused on investing in commercial-stage life sciences companies.

Cheetah Medical Secures $5 Million Investment from HighCape Partners

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013.

Cheetah Medical appoints Massachusetts General Hospital physician, Douglas M. Hansell, MD, MPH, as Chief Physician Executive

Cheetah Medical has appointed Douglas M. Hansell, MD, MPH, Assistant Clinical Professor of Anesthesia at Massachusetts General Hospital, as Chief Physician Executive.

Study* Shows $3+ of Costs Can Be Avoided by Hospitals for Every $1 They Spend During Surgery by Using Noninvasive Hemodynamic Monitoring

Cheetah Medical announced that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.

Cheetah Medical Expands Product Line, Introduces “Starling™ SV” Noninvasive Hemodynamic Monitoring System

Cheetah Medical has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.

Cheetah Medical says its growth is outpacing global market for hemodynamic monitoring systems, expected to reach $1.1 billion by 2019, according to market research firm MarketsandMarkets

Cheetah Medical announced that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets.

CHEETAH MEDICAL INTRODUCES STARLING SV NONINVASIVE HEMODYNAMIC MONITORING SYSTEM

Cheetah Medical, a privately held and rapidly growing medical device company, announced today that it has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasivehemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.

CHEETAH MEDICAL SAYS ITS GROWTH IS OUTPACING GLOBAL MARKET FOR HEMODYNAMIC MONITORING SYSTEMS

Cheetah Medical, a privately held and rapidly growing medical device company, announced today that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets, the world’s No. 2 firm in terms of annually published premium market research reports.

DUKE UNIVERSITY STUDY SHOWS $3+ OF COSTS AVOIDED FOR EVERY $1 THEY SPEND USING NONINVASIVE HEMODYNAMIC MONITORING DURING SURGERY

Cheetah Medical, a rapidly growing medical device company, announced today that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.

KEY CLINICIANS RECOGNIZE THE CLINICAL AND ECONOMIC BENEFITS OF NONINVASIVE VOLUME MANAGEMENT

Cheetah Medical, a rapidly growing medical device company, announced today that key opinion leading physicians are recognizing the significant clinical and economic benefits of noninvasive hemodynamic monitoring during perioperative fluid management.

BOSTON BUSINESS JOURNAL SPEAKS TO CHEETAH MEDICAL CEO CHRIS HUTCHISON

Cheetah Medical Inc., a Newton-based company making non-invasive blood monitoring system, received $5 million in venture capitalist funding from HighCape Partners.

CHEETAH MEDICAL SECURES $5 MILLION INVESTMENT FROM HIGHCAPE PARTNERS

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013. HighCape is a growth equity firm with a specialized focus and partner expertise in transforming commercial-stage life sciences companies into sustainable businesses.